Merck chooses a new strategy: restructuring the business ahead of patent protection expiration

Pharmaceutical giant Merck is taking decisive steps to adapt to market changes. Ahead of the expiration of key patents, the company plans to split its core pharmaceutical division into two independent entities. According to an analysis by Bloomberg, this move is a strategic maneuver aimed at optimizing operations before losing exclusivity on one of the company’s most profitable drugs.

The Need for Restructuring Amid Patent Challenges

Splitting the pharmaceutical division will allow Merck to better manage risks associated with market deregulation after patent expirations. This organizational transformation involves refocusing research and development efforts and commercial operations, which could facilitate faster development of new drugs. This approach demonstrates the company’s proactive stance in a rapidly changing pharmaceutical industry.

Maintaining Competitive Advantage Through Innovation

The main goal of the split is to focus one division on developing innovative solutions, while the other can optimize the production and logistics of existing drugs. This differentiation will enable the company to invest in future technologies while effectively managing its current drug portfolio. Merck’s strategy reflects the necessity for pharmaceutical companies to adapt to a new reality where losing exclusivity does not mean the end of the company, but rather requires rethinking the business model to ensure long-term growth and sustainability in the global market.